Bortezomib-associated demyelinating neuropathy--clinical and pathologic features
| Autor: | Eduardo A. De Sousa, Louis H. Weimer, Thomas H. Brannagan, Sujata Thawani, Kurenai Tanji |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Pathology medicine.medical_specialty Neural Conduction Antineoplastic Agents Bortezomib Polyneuropathies immune system diseases hemic and lymphatic diseases medicine Humans Multiple myeloma Aged Nerve biopsy medicine.diagnostic_test business.industry General Medicine Middle Aged Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Lymphoma Peripheral neuropathy Neurology Proteasome inhibitor Demyelinating neuropathy Female Neurology (clinical) business Multiple Myeloma Axonal degeneration medicine.drug Demyelinating Diseases |
| Zdroj: | Journal of clinical neuromuscular disease. 16(4) |
| ISSN: | 1537-1611 |
| Popis: | Objectives Bortezomib is a proteasome inhibitor that is frequently used for multiple myeloma and lymphoma. A sensory predominant axonal neuropathy is associated with bortezomib treatment but a demyelinating neuropathy is also described primarily based on electrodiagnostic findings. We report a series of patients treated with bortezomib who developed peripheral neuropathy and were found to have demyelinating features on electrodiagnostic testing. Methods Four patients who developed a bortezomib-induced peripheral neuropathy underwent electrophysiological testing, and 1 patient had a nerve biopsy. Results The four patients with bortezomib-induced peripheral neuropathy had demyelinating features on their electrophysiological testing. The nerve biopsy performed in 1 patient demonstrated a demyelinating component in a background of axonal degeneration. Conclusions Although most toxic neuropathies are symmetrical axonal neuropathies, bortezomib is part of a small list of agents that may cause a demyelinating polyneuropathy and axonal degeneration. These findings have been confirmed by nerve biopsy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|